By Stu Hutson

In the US, the question of whether or not pharmaceutical companies should be able to pay off competitors challenging their patent exclusivity may now be left to Congress.

“The effort has been fought to a stalemate in the courts,” says Lauren Fuller, director of legislative affairs for the Academy of Managed Care Pharmacy, a managed-care advocacy group that supports outlawing such ‘pay-for-delay’ deals. “We need to take care of this legislatively.” (Click here to continue reading)

Image by Rodrigo Soldon via Flickr Creative Commons